<scp>NLX</scp>‐112 Randomized <scp>Phase 2A</scp> Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy
These results support further clinical investigation of NLX-112 for treatment of PD LID. © 2025 Neurolixis SAS. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Authors
- Per Odin (ORCID: https://orcid.org/0000-0002-0756-7478)
- Steve A. Johnson (ORCID: https://orcid.org/0000-0001-9256-4505)
- Måns Jergil
- Per Svenningsson (ORCID: https://orcid.org/0000-0001-6727-3802)
- Filip Bergquist (ORCID: https://orcid.org/0000-0002-3437-0267)
- Karin Wirdefeldt (ORCID: https://orcid.org/0000-0002-5378-6364)
- Adrian Newman‐Tancredi (ORCID: https://orcid.org/0000-0002-2923-5714)
- Dag Nyholm (ORCID: https://orcid.org/0000-0001-9776-7715)
- Ioanna Markaki (ORCID: https://orcid.org/0000-0003-3328-5746)
- Mattias Andréasson (ORCID: https://orcid.org/0000-0003-3472-3947)
- Mark A. Varney (ORCID: https://orcid.org/0000-0002-7818-5266)
- Anders Johansson (ORCID: https://orcid.org/0000-0002-3928-5184)
- Christopher Jankosky
- Fabienne Herbrecht
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Neurolixis (United States) (US)
- Skåne University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Movement Disorders
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1002/mds.30175
- Citations
- 9
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.50
Funders
- Michael J. Fox Foundation for Parkinson's Research
- Parkinson's UK